ASCO23 Meeting

https://www.nejm.org/doi/full/10.1056/NEJMoa2301665?

https://www.nejm.org/doi/full/10.1056/NEJMoa2304594?

https://www.nejm.org/doi/full/10.1056/NEJMoa2304194?

https://www.nejm.org/doi/full/10.1056/NEJMoa2303269?

https://www.nejm.org/doi/full/10.1056/NEJMoa2303379?

https://www.nejm.org/doi/full/10.1056/NEJMoa2302983?

 

Studio EV-103 Enfortumab + Pembrolizumab

https://meetings.asco.org/abstracts-presentations/218065

Studio CHRYSALIS  Amivantamab + Lazertinib

https://meetings.asco.org/abstracts-presentations/218855

Studio DISCOVARY  Darolutamide

https://meetings.asco.org/abstracts-presentations/218558

Studio ARASENS Darolutamide

https://meetings.asco.org/abstracts-presentations/222950

Larotrectinib

https://meetings.asco.org/abstracts-presentations/218863

https://meetings.asco.org/abstracts-presentations/224722

Erdafitinib

https://meetings.asco.org/abstracts-presentations/218016

Dorstalimab

https://meetings.asco.org/abstracts-presentations/218587